NextCure, Inc. announced the appointments of Elizabeth Jaffee, M.D., Ursula Matulonis, M.D., and Weiping Zou, M.D., Ph.D., to its Scientific Advisory Board (SAB). Ethan Shevach, M.D., will retire from the SAB. Drs. Lieping Chen, M.D., Ph.D., Mario Sznol, M.D., and Stephen Miller, Ph.D., will continue to serve on the SAB. Dr. Jaffee is Deputy Director of the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, the Dana and Albert “Cubby” Broccoli Professor of Oncology at Johns Hopkins University and an international leader in immune based therapies. Dr. Jaffee’s research is focused on the development of novel vaccine approaches that overcome immune tolerance to cancers, and she has completed multiple studies testing an allogeneic tumor vaccine in patients with pancreatic cancer. She also established Johns Hopkins’ Cell Processing and Gene Therapy cGMP Facility, and currently holds six vaccine patents. Dr. Matulonis is Chief of the Division of Gynecologic Oncology at the Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School. She is the first recipient of the Brock-Wilson Family Chair at the Dana-Farber Cancer Institute. Dr. Matulonis co-leads the Gynecologic Cancer Program within the Dana-Farber/Harvard Cancer Center and the Ovarian Cancer Specialized Program in Research Excellence (SPORE) grant from the National Cancer Institute. Her research is focused on developing new targeted therapies for gynecologic malignancies, with a specific interest in ovarian cancer and endometrial cancer. Dr. Zou is the Charles B. de Nancrede Professor; Professor of Pathology, Immunology, Biology and Surgery; Director of the Center of Excellence for Cancer Immunology and Immunotherapy; and Co-Director of the Cancer Hematopoiesis and Immunology Program at the University of Michigan School of Medicine and Rogel Cancer Center. Dr. Zou leads a multidisciplinary laboratory that investigates the human cancer microenvironment with the goal of understanding the nature of human tumor immune responses and developing mechanism-informed combination therapies for cancer. His laboratory has demonstrated that the interaction between tumor cells and the host immune system fosters tumor immunosuppressive networks and results in cancer progression and therapeutic resistance.
NextCure, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on advancing medicines that treat cancer patients that do not respond to, or have disease progression on, current therapies, through the use of differentiated mechanisms of actions including Antibody-Drug Conjugates (ADCs), antibodies, and proteins. The Company focuses on advancing therapies that leverage its core strengths in understanding biological pathways and biomarkers, the interactions of cells, including in the tumor microenvironment, and the role each interaction plays in a biologic response. Its product candidates include NC410 and LNCB74. Its Clinical Oncology Programs are NC525 and NC318. Its Pre-Clinical Non-Oncology Programs are NC605 and NC181. NC410 is a LAIR-2 fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers. NCB74 is an ADC that is directed to B7-H4, a clinically validated cancer target.
NEXTCURE, INC. 
